TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30289374

Group type: EXPERIMENTAL
Intervention: Family meetings as a prevention strategy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Resilience-focused family intervention (Our Family Our Future)
Number of subjects: 82
Study: 30289425

Group type: EXPERIMENTAL
Intervention: Whey protein (WP) supplementation (30 g, 2 times/d)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Collagen peptides (CP) supplementation (30 g, 2 times/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Energy restriction (ER; -500 kcal/d) followed by ER with step reduction (ER + SR; <750 steps/d)
Number of subjects: 31
Study: 30289433

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 124707

Group type: EXPERIMENTAL
Intervention: AMED diet
Number of subjects: 124707

Group type: EXPERIMENTAL
Intervention: AHEI-2010 diet
Number of subjects: 124707

Group type: EXPERIMENTAL
Intervention: DASH diet (men)
Number of subjects: 124707

Group type: EXPERIMENTAL
Intervention: AMED diet (men)
Number of subjects: 124707

Group type: EXPERIMENTAL
Intervention: AHEI-2010 diet (men)
Number of subjects: 124707

Group type: EXPERIMENTAL
Intervention: DASH diet (women)
Number of subjects: 124707

Group type: EXPERIMENTAL
Intervention: AMED diet (women)
Number of subjects: 124707

Group type: EXPERIMENTAL
Intervention: AHEI-2010 diet (women)
Number of subjects: 124707
Study: 30289500

Group type: EXPERIMENTAL
Intervention: Self-measured arm circumference (CIRself_home)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Self-measured arm circumference (CIRself_lab)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Self-measured arm volume (VOLself_lab)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Self-managed surveillance for BCRL
Number of subjects: 41
Study: 30289497

Group type: EXPERIMENTAL
Intervention: Induced anxiety during MID task
Number of subjects: 0
Study: 30289507

Group type: COMPARATOR
Intervention: Normal ovulatory cycles (normal OVs)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Anovulatory cycles (ANOVs)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Short luteal phase ovulatory cycles (short OVs)
Number of subjects: 23
Study: 30289805

Group type: EXPERIMENTAL
Intervention: TriMix-100 g
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: TriMix-300 g
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: TriMix-300 g with HTI-300 g
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: TriMix-300 g with HTI-600 g
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: TriMix-300 g with HTI-900 g
Number of subjects: 21
Study: 30290003

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 1121
Study: 30290121

Group type: EXPERIMENTAL
Intervention: Financial incentives for smoking cessation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cessation aids
Number of subjects: 0
Study: 30290794

Group type: EXPERIMENTAL
Intervention: Intrathecal hydromorphone
Number of subjects: 20
Study: 30290829

Group type: EXPERIMENTAL
Intervention: Noise levels in the ICU
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Restorative periods
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 64
Study: 30291058

Group type: EXPERIMENTAL
Intervention: Health technology-supported self-management program involving telemonitoring and health counseling
Number of subjects: 166

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 166
Study: 30291086

Group type: EXPERIMENTAL
Intervention: Technology use in diabetes management
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Access to technology
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Ownership of a home computer
Number of subjects: 260
Study: 30291092

Group type: EXPERIMENTAL
Intervention: OneTouch Verio Flex glucose meter with OneTouch Reveal diabetes app
Number of subjects: 137

Group type: COMPARATOR
Intervention: OneTouch Verio Flex glucose meter alone
Number of subjects: 137
Study: 30291094

Group type: EXPERIMENTAL
Intervention: Phone Messaging (PM)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Phone Messaging plus Family and Friends Support (PM+FF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 30291112

Group type: EXPERIMENTAL
Intervention: Eculizumab 600 mg weekly for 4 weeks, then 900 mg every other week through week 26
Number of subjects: 13
Study: 30291369

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily ± dasabuvir 250 mg twice daily ± ribavirin 200 mg once daily for 12 or 24 weeks
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir, dasabuvir, and ribavirin
Number of subjects: 86
Study: 30291377

Group type: EXPERIMENTAL
Intervention: Doppler-based resistive index (RI)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Semi-quantitative evaluation of renal perfusion (SQP)
Number of subjects: 371
Study: 30291379

Group type: EXPERIMENTAL
Intervention: Higher neutrophil CD279
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Higher monocyte CD279
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Lower monocyte HLA-DR
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Increased neutrophil CD24 and neutrophil CD279, reduced monocyte HLA-DR expression
Number of subjects: 272
Study: 30291587

Group type: EXPERIMENTAL
Intervention: Duodenojejunostomy ± distal duodenum resection
Number of subjects: 39
Study: 30291761

Group type: EXPERIMENTAL
Intervention: CAMS
Number of subjects: 98

Group type: COMPARATOR
Intervention: E-CAU
Number of subjects: 98
Study: 30291831

Group type: EXPERIMENTAL
Intervention: HeartMate 3 left ventricular assist device (ELEVATE registry)
Number of subjects: 463

Group type: COMPARATOR
Intervention: HeartMate 3 left ventricular assist device (CEM trial)
Number of subjects: 463
Study: 30291834

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine toothbrushing three times daily for 5 days before and after surgery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Time-matched control group (no specific intervention mentioned)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine toothbrushing
Number of subjects: 62
Study: 30291925

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT scans (0.14 mSv)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard-dose CT scans (3.4 mSv)
Number of subjects: 105
Study: 30292492

Group type: EXPERIMENTAL
Intervention: Cranial ultrasonography and near-term MRI
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Presence of lesions on near-term MRI
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Positive screens on Competence scores
Number of subjects: 397
Study: 30292651

Group type: EXPERIMENTAL
Intervention: MR haplotype 1 (G-A haplotype)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: MR haplotypes
Number of subjects: 469
Study: 30292675

Group type: EXPERIMENTAL
Intervention: Adapted ketogenic diet (AKD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 30293206

Group type: EXPERIMENTAL
Intervention: Testosterone deficiency defined by total testosterone (TT) levels < 300 ng/dL and/or bioavailable testosterone (BT) levels < 80 ng/dL
Number of subjects: 1343

Group type: EXPERIMENTAL
Intervention: Testosterone deficiency (TT and/or BT levels)
Number of subjects: 1343

Group type: EXPERIMENTAL
Intervention: Bioavailable testosterone (BT) levels
Number of subjects: 1343
Study: 30293228

Group type: EXPERIMENTAL
Intervention: Innovative treatment strategies for diabetic retinopathy targeting retinal neuroprotection, promoting neuronal regeneration, and re-programming retinal cell types into functional neurons.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular mechanisms and potential biomarkers associated with retinal neuronal degeneration in diabetes.
Number of subjects: 0
Study: 30293250

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging (FI)
Number of subjects: 19
Study: 30293640

Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome (BBS) subjects with thoraco-abdominal abnormalities
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome (BBS) subjects with congenital heart disease
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome (BBS) subjects with additional defects
Number of subjects: 368
Study: 30293873

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab (discovery cohort)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab (validation cohort)
Number of subjects: 451

Group type: COMPARATOR
Intervention: FOLFIRI plus cetuximab (control cohort)
Number of subjects: 451
Study: 30294448

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 246
Study: 30294474

Group type: EXPERIMENTAL
Intervention: Balloon-mounted stent
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Balloon plus self-expanding stent
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall (both interventions)
Number of subjects: 300
Study: 30294552

Group type: EXPERIMENTAL
Intervention: Insulin pump therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 156
Study: 30294699

Group type: EXPERIMENTAL
Intervention: Fit&Trim (DPP-based) intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 67
Study: 30294708

Group type: EXPERIMENTAL
Intervention: 4.8 g/day multimatrix mesalamine tablets once daily for eight weeks (acute phase)
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: 2.4 g/day multimatrix mesalamine for 12 months (maintenance phase)
Number of subjects: 717

Group type: COMPARATOR
Intervention: Comparison of SF-12v2 scores to the U.S. general population
Number of subjects: 717

Group type: COMPARATOR
Intervention: Mixed-effects repeated-measures models
Number of subjects: 717
Study: 30295389

Group type: EXPERIMENTAL
Intervention: Episodic treatment (n=75)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment (n=28)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: aPCC prophylaxis
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Serious adverse events (AEs)
Number of subjects: 103
Study: 30295700

Group type: EXPERIMENTAL
Intervention: Cow milk formula (CMF)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Extensively protein hydrolyzed formula (EHF)
Number of subjects: 113
Study: 30295816

Group type: EXPERIMENTAL
Intervention: Oral clomiphene citrate (50 mg) once daily for 30 days
Number of subjects: 12
Study: 30295822

Group type: EXPERIMENTAL
Intervention: Asymptomatic malaria infections with P. cynomolgi
Number of subjects: 5422

Group type: EXPERIMENTAL
Intervention: Asymptomatic malaria infections with P. knowlesi
Number of subjects: 5422

Group type: EXPERIMENTAL
Intervention: Asymptomatic malaria infections with both P. vivax and P. cynomolgi
Number of subjects: 5422

Group type: EXPERIMENTAL
Intervention: Asymptomatic reappearance of P. cynomolgi
Number of subjects: 5422

Group type: EXPERIMENTAL
Intervention: Overall asymptomatic malaria infections
Number of subjects: 5422
Study: 30296432

Group type: EXPERIMENTAL
Intervention: NICE classification system
Number of subjects: 1634
Study: 30296681

Group type: EXPERIMENTAL
Intervention: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine followed by TA-HPV boost through skin scarification
Number of subjects: 0
Study: 30296735

Group type: EXPERIMENTAL
Intervention: Opioid use (yes)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Pain intensity (stronger)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Pain intensity (mild)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Pain intensity (moderate to severe)
Number of subjects: 144
Study: 30296840

Group type: EXPERIMENTAL
Intervention: Migraine with aura patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study: 30297124

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV) administered at 0, 2, and 6 months
Number of subjects: 189

Group type: COMPARATOR
Intervention: Historical controls (HIV-1-negative cohorts from Africa and HIV-1 positive adolescent cohorts from the USA)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV)
Number of subjects: 189
Study: 30297385

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg orally every day plus bortezomib 1.3 mg/m² IV on days 1, 4, 8, and 11 of a 28-day cycle
Number of subjects: 22
Study: 30297539

Group type: EXPERIMENTAL
Intervention: FRED Embolic device
Number of subjects: 103
Study: 30297543

Group type: EXPERIMENTAL
Intervention: LVIS stent system (LVIS and LVIS Junior) used for coil embolization
Number of subjects: 153
Study: 30297879

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) treatment
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Anaemia during postnatal week 1
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Gestational age (GA)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Elevated EPO levels postnatal day 7
Number of subjects: 78
Study: 30298037

Group type: EXPERIMENTAL
Intervention: Treatment for Insomnia Severity, details not available
Number of subjects: 0
Study: 30298065

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30298070

Group type: EXPERIMENTAL
Intervention: 100 mg of 20-30% iron-saturated bovine lactoferrin (bLf) twice a day
Number of subjects: 198

Group type: COMPARATOR
Intervention: 329.7 mg of ferrous sulfate once a day (control)
Number of subjects: 198
Study: 30298340

Group type: EXPERIMENTAL
Intervention: Immunosignature analysis using a 256-peptide signature derived from serum antibodies.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Immunosignature analysis using a 654-peptide signature derived from serum antibodies.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Testing of the immunosignature in international data sets.
Number of subjects: 25
Study: 30298381

Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (RT) at a total dose of 20 Gy delivered BID in two consecutive days.
Number of subjects: 54
Study: 30298444

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.5 pmol/kg/min dissolved in 500 ml of 0.9% saline)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (500 ml of 0.9% saline)
Number of subjects: 14
Study: 30298462

Group type: EXPERIMENTAL
Intervention: Verbal prompt for facial expression production
Number of subjects: 0
Study: 30298568

Group type: EXPERIMENTAL
Intervention: Non-obese nonalcoholic fatty liver disease
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Non-obese nonalcoholic steatohepatitis
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Predictors of nonalcoholic steatohepatitis in non-obese subjects
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Predictors of significant fibrosis in non-obese subjects
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Sagittal abdominal diameter
Number of subjects: 664
Study: 30298593

Group type: EXPERIMENTAL
Intervention: Self-expandable sirolimus-eluting stents (SES)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Second-generation drug-eluting stents (DES-II)
Number of subjects: 151
Study: 30298796

Group type: EXPERIMENTAL
Intervention: Anaemic child and overweight mother
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Anaemic child and obese mother
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Co-occurrence of anaemia in child and excess adiposity in mother
Number of subjects: 437
Study: 30299161

Group type: EXPERIMENTAL
Intervention: Pre-PLS patients
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Patients with longstanding primary lateral sclerosis
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pre-PLS patients (initial scans)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Follow-up scans in pre-PLS patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 13

Group type: COMPARATOR
Intervention: Patients with longstanding disease
Number of subjects: 13
Study: 30299230

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous (iv) alteplase (0.6 mg/kg body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure (BP) lowering (systolic target 130-140 mmHg)
Number of subjects: 0
Study: 30300158

Group type: EXPERIMENTAL
Intervention: Earlens system (light-driven contact hearing aid)
Number of subjects: 78
Study: 30300264

Group type: EXPERIMENTAL
Intervention: Mesopic testing at distances of 0.43°, 0.86°, 1.29°, 2.15°, and 3.01°
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dark-adapted cyan sensitivity
Number of subjects: 25
Study: 30300751

Group type: EXPERIMENTAL
Intervention: Fully-automatic segmentation framework for spinal cord and intramedullary MS lesions from MRI data.
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Conventional MRI data of MS and non-MS cases.
Number of subjects: 1042
Study: 30301763

Group type: EXPERIMENTAL
Intervention: Age (18-25 years)
Number of subjects: 49603

Group type: EXPERIMENTAL
Intervention: Age (18-39 years)
Number of subjects: 49603

Group type: EXPERIMENTAL
Intervention: Having postsecondary education
Number of subjects: 49603

Group type: EXPERIMENTAL
Intervention: Being a student
Number of subjects: 49603

Group type: EXPERIMENTAL
Intervention: Living alone, low education, low physical activity, being a homemaker/disabled/unemployed/retired, a manual worker or a former/current smoker
Number of subjects: 49603
Study: 30302121

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 37

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 37
Study: 30302374

Group type: EXPERIMENTAL
Intervention: Linked color imaging
Number of subjects: 0
Study: 30302599

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily with mFOLFOX-6 + bevacizumab
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Everolimus 7.5 mg daily with mFOLFOX-6 + bevacizumab (recommended phase II dose)
Number of subjects: 35
Study: 30302762

Group type: EXPERIMENTAL
Intervention: NIPS (noninvasive programmed ventricular stimulation)
Number of subjects: 105
Study: 30304477

Group type: EXPERIMENTAL
Intervention: Reducing Disability in Alzheimer's Disease-NorthWest (RDAD-NW) intervention
Number of subjects: 255
Study: 30304513

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 3493
Study: 30304652

Group type: EXPERIMENTAL
Intervention: ex vivo-expanded, partially HLA-matched, third-party-produced, cryopreserved BK virus-specific T cells
Number of subjects: 3
Study: 30305055

Group type: EXPERIMENTAL
Intervention: Obatoclax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRAIL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of obatoclax and TRAIL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lapatinib
Number of subjects: 0
Study: 30305103

Group type: EXPERIMENTAL
Intervention: Online Emotion Regulation Individual Therapy for Adolescents (ERITA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Online therapist-guided parent program
Number of subjects: 25
Study: 30305183

Group type: EXPERIMENTAL
Intervention: PlasmaBlade
Number of subjects: 20
Study: 30305346

Group type: EXPERIMENTAL
Intervention: Control-IQ Technology (Tandem Diabetes Care)
Number of subjects: 5
Study: 30305449

Group type: EXPERIMENTAL
Intervention: Intrathecal rituximab (25 mg with a 1-week interval)
Number of subjects: 23
Study: 30305890

Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Standard intraoperative fluid management (Control)
Number of subjects: 401
Study: 30305961

Group type: EXPERIMENTAL
Intervention: Nitrate-rich fruit and vegetable liquid supplement (FVS, AMPED NOx, Isagenix International LLC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Juice low in nitrates (prune juice, PRU)
Number of subjects: 45
Study: 30305980

Group type: EXPERIMENTAL
Intervention: BRNS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Butterfly strip
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prototype strips
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All strips (BRNS, Butterfly, Prototype)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All strips (BRNS, Butterfly)
Number of subjects: 50
Study: 30306125

Group type: EXPERIMENTAL
Intervention: Hu08BBz CAR T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hu13Rα2 CAR T cells with CTLA-4 blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFRvIII CAR T cells with PD-1 and TIM-3 blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hu07BBz CAR T cells
Number of subjects: 0
Study: 30306144

Group type: EXPERIMENTAL
Intervention: Intensive complementary feeding intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 30306221

Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in AS patients
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Serum matrix metalloproteinase-3 (MMP-3) in AS patients
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Serum vascular endothelial growth factor (VEGF) in AS patients
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis of serum HGF
Number of subjects: 204

Group type: COMPARATOR
Intervention: Comparison of serum HGF levels between male AS patients and HC
Number of subjects: 204
Study: 30306423

Group type: EXPERIMENTAL
Intervention: Copenhagen Baby Heart Study (CBHS) intervention including echocardiographic examination, electrocardiography, and post-ductal pulse oximetry shortly after birth.
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Referral to a specialist or hospital admission for infants diagnosed with significant CHD based on severity.
Number of subjects: 25000
Study: 30306534

Group type: EXPERIMENTAL
Intervention: Hearing loss in survivors of CNS tumours
Number of subjects: 700

Group type: COMPARATOR
Intervention: Hearing loss in survivors of other cancers
Number of subjects: 700
Study: 30306834

Group type: EXPERIMENTAL
Intervention: Personalized community-based physical activity intervention (16 weeks)
Number of subjects: 46
Study: 30307350

Group type: EXPERIMENTAL
Intervention: 100 mL of 20% intravenous lipid emulsion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Number of subjects: 40
Study: 30307465

Group type: EXPERIMENTAL
Intervention: Umbrella biomarker-driven study
Number of subjects: 0
Study: 30307609

Group type: EXPERIMENTAL
Intervention: Locally tailored clinical guidelines
Number of subjects: 188